The sentinel node biopsy in early gastric cancer: a preliminary study

Abstract

The detection rate of this procedure was 100%. The preliminary results and perspectives for feasibility of sentinel node biopsy and its accuracy in predicting the nodal status in early gastric cancer are discussed.

Is the sentinel node biopsy clinically applicable for limited lymphadenectomy and modified gastric resection in gastric cancer? A meta‐analysis of feasibility studies

“…Finally, 46 feasibility studies involving 2,684 patients were enrolled in this meta‐analysis. The details of these 46 studies are provided in Table I 18–63.…”

Imaging in assessing lymph node status in gastric cancer

“…A disadvantage of laparoscopic SN biopsy, however, is its invasiveness. Although studies on laparoscopic SN biopsy have shown its potential [76][77][78][79], various technical and material limitations still have to be overcome. Also, the reliability of laparoscopic SN biopsy has yet to be determined by multicenter prospective clinical trials [80].…”

Systematic Review of Studies Investigating Sentinel Node Navigation Surgery and Lymphatic Mapping for Gastric Cancer

“…First, the general preference to visualize SLNs has shifted toward a double-tracer (dye plus isotope) method. [32][33][34]36,40,44,47,52 Many researchers have reported substantial improvement by the combined use of both techniques in the rate of identification of SLNs, [32][33][34]47,53,58 although some authors did not agree with that idea. 40 Hayashi et al 10 stated that a reduction in the SR would result if either the dye-guided or radioguided method was used solely.…”

“…Ishizaki et al 30 Prospective Park et al 31 Prospective comparison Lee et al 32 Prospective Mura et al 33 Prospective Saikawa et al 34 Prospective 2007…”

“…Kelder et al 55 Prospective comparison Jeong et al 56 - 33 2006 Italy 10 Patent blue violet + 99m Tc tin C 100 3.1 Saikawa et al 34 2006 Japan 35 Isosulfan blue + 99m Tc tin C 94.3 3.9 Ohdaira et al 35 2007 Japan 161 Indocyanine green + IREE --Morita et al 36 2007 Japan 53 Indocyanine green + 99m Tc tin C 100 4.6 Ishigami et al 37 2007 Japan 5 99m Tc tin C 100 2.6 Rino et al 38 2007 Japan 43 Patent blue violet 93 3.5 Gretschel et al 40 2007 Germany 35 Patent blue violet + 99m Tc tin C 97 b Ishikawa et al 42 2007 Japan 16 Indocyanine green + IREE 100 2.9 Yaguchi et al 44 2008 Japan 63 Indocyanine green + 99m Tc tin C 98.4 4 Miyashiro et al 45 2008 Japan 3 Indocyanine green + IR + FI 100 -Orsenigo et al 46 2008 Italy 34 Patent blue violet 80 1.5 Lee et al 47 2008 Korea 21 Indocyanine green + 99m Tc tin C 54.8 e 2.1 e Lee et al 47 2008 Korea 21 Indocyanine green + 99m Tc tin C 96 f 3.5 f Tajima et al 49 2009 Japan 133 Indocyanine green + FI 97.3 d 7.1 d Tajima et al 49 2009 Japan 133 Indocyanine green + FI 94.7 g 7.7 g Ichikura et al 51 2009 Japan 56 Indocyanine green + 99m Tc tin C (SM or SS) 100 7.8 Ohdaira et al 52 2009 Japan 35 Indocyanine green + IREE 100 -Park et al 53 2010 For stage cT2-3 tumors. FI, fluorescence imaging; IR, infrared imaging videoscope; IREE, infrared ray electronic endoscopy; SR, success rate (refers to the ability of the method to identify SLNs in relation to the whole study population); SM, submucosal injection; SS, subserosal injection; 99m Tc ASC, technetium-99m radiolabeled antimony sulfur colloid; 99m Tc SC, technetium-99m radiolabeled sulfur colloid; 99m Tc tin C, technetium-99m radiolabeled tin colloid.…”